Page 41 - GALENIKA MEDICAL JOURNAL

15. Barrios V, Navarro A, Esteras A, Luque M, Romero J, Tamargo J, et al; 20. Liang L, Kung JY, Mitchelmore B, Cave A, Banh HL. Comparative
Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de peripheral edema for dihydropyridines calcium channel blockers
Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in treatment: A systematic review and network meta-analysis. J Clin
daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Hypertens (Greenwich). 2022 May;24(5):536-54.
Perfil de Seguridad. Blood Press. 2002;11(2):95-100.
21. Schütze A, Benöhr P, Haubitz M, Radziwill R, Hohmann C. Development
16. Romito R, Pansini MI, Perticone F, Antonelli G, Pitzalis M, Rizzon P. of a list with renally relevant drugs as a tool to increase medicines
Comparative effect of lercanidipine, felodipine, and nifedipine GITS on optimisation in patients with chronic kidney disease. Eur J Hosp Pharm.
blood pressure and heart rate in patients with mild to moderate arterial 2023 Jan;30(1):46-52.
hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens
(Greenwich). 2003 Jul-Aug;5(4):249-53.
17. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, et al. Konflikt interesa: Nema
Effect of lercanidipine compared with ramipril on albumin excretion
rate in hypertensive Type 2 diabetic patients with microalbuminuria: Primljeno: 26. 02. 2023.
DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes
Nutr Metab. 2004 Oct;17(5):259-66. Prihvaćeno: 04. 03. 2023.
18. Barrios V, Escobar C, de la Figuera M, Honorato J, Llisterri JL, Segura Onlajn: 01. 06. 2023.
J, et al. High doses of lercanidipine are better tolerated than other
dihydropyridines in hypertensive patients with metabolic syndrome:
results from the TOLERANCE study. Int J Clin Pract. 2008 May;62(5):723-
8.
19. Marjanovic M, Stojanov V, Marjanovic I, Vukcevic-Milosevic G,
Radivojevic N, Matic D. Age- and Gender-Related Differences in the
Hemodynamic Status of Patients with Mild or Moderate Hypertension.
Int J Gen Med. 2022 Jul 5;15:6043-53.

REVIJALNI RADOVI Galenika Medical Journal, 2023; 2(6):35-39. 39